{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:51:09Z","timestamp":1788868269738,"version":"build-2803163510"},"reference-count":15,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,10]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Ten of 36 patients (28%) achieved an OS \u226530 months in a blinatumomab study in relapsed\/refractory acute lymphoblastic leukemia. Long-term survival may be associated with T-cell expansion, B-cell depletion, and a minimal residual disease response.<\/jats:p>","DOI":"10.1182\/blood-2015-06-649111","type":"journal-article","created":{"date-parts":[[2015,10,20]],"date-time":"2015-10-20T00:34:24Z","timestamp":1445301264000},"page":"2578-2584","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":145,"title":["Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment"],"prefix":"10.1182","volume":"126","author":[{"given":"Gerhard","family":"Zugmaier","sequence":"first","affiliation":[{"name":"Amgen Research (Munich), Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"G\u00f6kbuget","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Goethe University Frankfurt, Frankfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Klinger","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich), Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Viardot","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[{"name":"Department of Medicine A, University of M\u00fcnster, M\u00fcnster, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"Neumann","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Christian-Albrechts-Universit\u00e4t zu Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-A.","family":"Horst","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Christian-Albrechts-Universit\u00e4t zu Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Marks","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Albert-Ludwigs-Universit\u00e4t Frieburg, Freiburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Faul","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Eberhard Karls Universit\u00e4t T\u00fcbingen, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Diedrich","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Medizinische Hochschule Hannover, Hannover, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Reichle","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University of Regensburg, Regensburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Br\u00fcggemann","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Christian-Albrechts-Universit\u00e4t zu Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Holland","sequence":"additional","affiliation":[{"name":"Amgen, Rockville, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich), Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"Department of Medicine II and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf C.","family":"Bargou","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Mainfranken, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max S.","family":"Topp","sequence":"additional","affiliation":[{"name":"Department of Medicine II and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2019111902194730100_B1","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","article-title":"Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial.","volume":"21","author":"Tavernier","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"2019111902194730100_B2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group.","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"2019111902194730100_B3","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study.","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"24","key":"2019111902194730100_B4","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1002\/cncr.25354","article-title":"Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration.","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"issue":"10","key":"2019111902194730100_B5","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2019111902194730100_B6","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.yexcr.2011.03.010","article-title":"Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab.","volume":"317","author":"Nagorsen","year":"2011","journal-title":"Exp Cell Res"},{"issue":"36","key":"2019111902194730100_B7","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111902194730100_B8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"18","key":"2019111902194730100_B9","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"key":"2019111902194730100_B10","article-title":"NCI common terminology criteria for adverse events (CTCAE) v4.0.","author":"National Cancer Institute"},{"issue":"5891","key":"2019111902194730100_B11","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"issue":"1","key":"2019111902194730100_B12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/sim.4780030106","article-title":"A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias.","volume":"3","author":"Simon","year":"1984","journal-title":"Stat Med"},{"issue":"15","key":"2019111902194730100_B13","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"issue":"224","key":"2019111902194730100_B14","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"2019111902194730100_B15","first-page":"33","article-title":"Re-exposure to blinatumomab after CD19-positive relapse: experience from three trials in patients (pts) with relapsed\/refractory B-precursor acute lymphoblastic leukemia (R\/R ALL) [abstract].","author":"Topp","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/126\/24\/2578\/1389787\/2578.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/126\/24\/2578\/1389787\/2578.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T02:20:01Z","timestamp":1574130001000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/126\/24\/2578\/34684\/Longterm-survival-and-Tcell-kinetics-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,10]]},"references-count":15,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2015,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2015-06-649111","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,10]]}}}